INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Recent Advances in Emulgel Technology for Enhanced Transdermal Drug Delivery

Swati Ojha*, Dr. Jyoti Yadav

Department Of Pharmacy, Institute of Technology and management, Gida, Gorakhpur, Uttar Pradesh, India.

ARTICLE INFO

Published: 01 Apr 2026

Keywords:

Emulgel, Nanoemulgel, Transdermal drug delivery system(TDDS), Niosomes,Hydrophilic and Lipophilic.

DOI:

10.5281/zenodo.19369102

ABSTRACT

Transdermal drug delivery has emerged as a promising alternative to conventional drug administration routes due to its ability to bypass first-pass metabolism, provide sustained drug release, and enhance patient compliance. However, the effectiveness of transdermal systems is often limited by the barrier function of the stratum corneum and the poor solubility of many therapeutic agents. In recent years, emulgel technology has gained significant attention as an innovative approach that combines the advantages of emulsions and gels to improve drug delivery performance. Emulgels enable the incorporation of both hydrophilic and lipophilic drugs, offering enhanced stability, controlled release, and improved permeation through the skin.This review highlights recent advances in emulgel technology for enhanced transdermal drug delivery, with a particular focus on formulation strategies, functional excipients, and novel carrier systems. Special emphasis is placed on nanoemulgels, stimuli-responsive systems, and the use of natural and biocompatible polymers, which have demonstrated improved drug bioavailability and therapeutic efficacy. Additionally, the review discusses various evaluation parameters, therapeutic applications, and current challenges associated with emulgel systems.Despite significant progress, issues related to formulation stability, large-scale production, and regulatory considerations remain critical. Future research directions are expected to focus on the development of smart and targeted emulgel systems to further optimize transdermal drug delivery. Overall, emulgel technology represents a versatile and evolving platform with substantial potential in modern pharmaceudetical applications.

INTRODUCTION

Transdermal drug delivery systems (TDDS) have gained considerable attention as an alternative to conventional routes of drug administration due to their ability to deliver drugs across the skin in a controlled and sustained manner. This approach offers several advantages, including avoidance of

***Corresponding Author:** Swati Ojha
Address: *Department Of Pharmacy, Institute of Technology and management, Gida, Gorakhpur, Uttar Pradesh, India*
Email : swati8546ojha @gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

first-pass metabolism, reduction in dosing frequency, improved bioavailability, and enhanced patient compliance. Despite these benefits, the effectiveness of transdermal delivery is significantly limited by the skin's natural barrier, particularly the stratum corneum, which restricts the permeation of most drugs, especially those with high molecular weight or poor solubility [1].To overcome these limitations, various formulation strategies and carrier systems have been developed, including liposomes, niosomes, microemulsions, and nanoparticles. Among these, emulgel technology has emerged as a promising and versatile platform for topical and transdermal drug delivery. Emulgels are biphasic systems that combine the properties of emulsions and gels, enabling the incorporation of both hydrophilic and lipophilic drugs within a single formulation. The emulsion component enhances the solubility of poorly water-soluble drugs, while the gel base provides improved stability, spreadability, and patient acceptability [2].In recent years, significant advancements have been made in emulgel technology to enhance drug permeation and therapeutic efficacy. The development of nanoemulgels, characterized by nanoscale droplet sizes, has improved drug absorption by increasing surface area and facilitating deeper penetration into the skin layers. Additionally, the use of novel polymers, penetration enhancers, and bio-based excipients has further optimized formulation performance. Emerging approaches such as stimuli-responsive and targeted emulgel systems have opened new possibilities for controlled and site-specific drug delivery [3].Furthermore, emulgels have demonstrated wide applicability in delivering various classes of drugs, including anti-inflammatory, antifungal, analgesic, and hormonal agents. Their ability to provide localized as well as systemic effects makes them a valuable tool in modern pharmaceutics. However, challenges related to formulation stability, scalability, and regulatory approval remain areas of ongoing research and development.This review aims to provide a comprehensive overview of recent advances in emulgel technology for enhanced transdermal drug delivery, focusing on formulation design, evaluation parameters, therapeutic applications, and future perspectives.

2. Skin as a Barrier to Drug Delivery

The skin is the largest organ of the human body and serves as a protective barrier against environmental hazards, pathogens, and chemical substances. While this barrier function is essential for maintaining physiological homeostasis, it also poses a significant challenge for transdermal drug delivery. The effectiveness of drug permeation through the skin is primarily governed by its complex structure, particularly the outermost layer, the stratum corneum. Understanding the structural and functional aspects of the skin is crucial for designing effective transdermal delivery systems such as emulgels.

2.1 Structure and Function of Skin

The skin consists of three main layers: the epidermis, dermis, and hypodermis. The epidermis is the outermost layer and is primarily responsible for the barrier function. It is further divided into several sublayers, including the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale. Among these, the stratum corneum plays a critical role in regulating drug permeation.The dermis lies beneath the epidermis and contains connective tissues, blood vessels, nerves, and lymphatics, which are essential for systemic drug absorption once the drug crosses the epidermal barrier. The hypodermis, composed mainly of adipose tissue, provides structural support and insulation. The primary function of the skin is to act as a physical and biochemical barrier while also regulating temperature and preventing water loss [1].

2.2 Barrier Properties of the Stratum Corneum

The stratum corneum is the principal barrier to transdermal drug delivery and is often described using the "brick and mortar" model, where corneocytes (dead keratinized cells) represent the bricks and the intercellular lipid matrix acts as the mortar. This highly organized lipid structure, composed mainly of ceramides, cholesterol, and free fatty acids, restricts the diffusion of both hydrophilic and lipophilic molecules.Drug permeation across the stratum corneum can occur via three main pathways: intercellular (through lipid domains), transcellular (through corneocytes), and appendageal (via hair follicles and sweat glands). Among these, the intercellular route is the most dominant. The barrier efficiency of the stratum corneum depends on factors such as lipid composition, hydration level, and thickness, making it the rate-limiting step in transdermal drug delivery [2].

2.3 Factors Affecting Transdermal Drug Permeation

Physicochemical properties of the drug: Molecular weight, lipophilicity (log P), and solubility play crucial roles. Ideally, drugs with molecular weight less than 500 Da and moderate lipophilicity exhibit better permeation.
Skin condition and hydration: Increased hydration of the stratum corneum enhances drug diffusion by disrupting lipid structure.
Age and anatomical site: Skin permeability varies with age and differs across body sites due to variations in thickness and lipid content.
Presence of penetration enhancers: Chemical enhancers, surfactants, and novel carriers such as emulgels can improve drug permeation by altering the skin barrier.
Formulation factors: Drug concentration, pH, and type of vehicle significantly affect drug release and absorption.
Understanding these factors is essential for optimizing transdermal formulations and improving drug bioavailability. Advanced delivery systems such as emulgels utilize these principles to enhance drug permeation and achieve better therapeutic outcomes

3. Emulgel Technology: Concept and Rationale

3.1 Concept of Emulgel

Emulgel is an advanced topical drug delivery system that combines the properties of emulsions and gels to overcome the limitations associated with conventional dosage forms. It is a biphasic system in which either an oil-in-water (O/W) or water-in-oil (W/O) emulsion is incorporated into a gel matrix using suitable gelling agents. This hybrid system enables the incorporation of both hydrophilic and lipophilic drugs, thereby enhancing formulation versatility and therapeutic applicability.In an emulgel system, the emulsion phase serves as a reservoir for lipophilic drugs, while the gel matrix provides structural stability, improved viscosity, and better patient acceptability. The presence of a gel base also enhances spreadability, bioadhesion, and retention time at the site of application. As a result, emulgels have gained significant attention as effective carriers for transdermal and topical drug delivery [1].

3.2 Rationale for Combining Emulsion and Gel Systems

The rationale behind the development of emulgel technology lies in addressing the limitations of both emulsions and gels when used independently. Emulsions are effective in solubilizing hydrophobic drugs but often suffer from stability issues such as phase separation, creaming, and coalescence. On the other hand, gels offer excellent patient compliance due to their non-greasy nature and ease of application but are generally limited to hydrophilic drug incorporation.By integrating an emulsion into a gel base, emulgels provide a stable and efficient delivery system that combines the advantages of both formulations. This combination improves drug loading capacity, enhances stability, and facilitates controlled drug release. Furthermore, the gel network helps in maintaining the integrity of the emulsion droplets, reducing instability issues and prolonging shelf life [2].

3.3 Advantages Over Conventional Topical Systems

Emulgels offer several advantages over traditional topical dosage forms such as ointments, creams, and gels:

- **Enhanced drug solubility:** Suitable for both hydrophilic and lipophilic drugs.
- **Improved stability:** Reduced chances of phase separation compared to conventional emulsions.
- **Better patient compliance:** Non-greasy, easily spreadable, and aesthetically acceptable.
- **Controlled and sustained release:** Enables prolonged therapeutic effect.
- **Enhanced skin permeation:** Presence of penetration enhancers and lipid phase facilitates drug transport across the skin barrier.
- **Ease of formulation and scalability:** Simple preparation methods and cost-effective production.

These advantages make emulgels a promising platform for transdermal drug delivery, particularly for drugs with poor water solubility and limited bioavailability [3].

3.4 Mechanism of Drug Release from Emulgel

Drug release from emulgels typically involves a multi-step process. Initially, the drug is released from the internal phase of the emulsion into the external gel matrix, followed by diffusion through the gel network and eventual permeation across the skin layers. The release mechanism is influenced by factors such as droplet size, viscosity of the gel, type of emulsifier, and drug solubility.

In most cases, drug release from emulgels follows diffusion-controlled kinetics, often described by models such as Higuchi or Korsmeyer–Peppas equations. The presence of a gel matrix helps in modulating drug release, ensuring sustained delivery over an extended period. Additionally, the incorporation of permeation enhancers and nanosized droplets can further facilitate drug penetration through the stratum corneum, improving therapeutic efficacy

4. Formulation Components and Their Functional Role

The performance, stability, and therapeutic efficacy of emulgel formulations are highly dependent on the appropriate selection of formulation components. Each component plays a distinct role in determining drug solubility, release kinetics, skin permeation, and overall formulation stability. The major components include oils, surfactants, gelling agents, penetration enhancers, and other excipients.

4.1 Oils and Lipid Phase Selection

The oil phase is a critical component in emulgel formulations, primarily responsible for solubilizing lipophilic drugs and influencing drug release behavior. Oils such as mineral oil, paraffin, castor oil, and vegetable oils are commonly used. The selection of oil not only affects drug solubility but also determines the occlusive properties, spreadability, and permeability of the formulation. The presence of an oil phase enhances skin hydration by forming an occlusive layer, thereby improving drug permeation through the stratum corneum .

Additionally, the type and concentration of oil influence the viscosity, stability, and therapeutic performance of the emulgel. Certain oils may also exhibit synergistic pharmacological effects, further enhancing the efficacy of the formulation .

4.2 Surfactants and Co-surfactants

Surfactants are essential for stabilizing the emulsion system by reducing interfacial tension between the oil and aqueous phases. Commonly used surfactants include non-ionic agents such as Tween (polysorbates) and Span (sorbitan esters), which are preferred due to their low toxicity and high compatibility with drugs .

Co-surfactants further enhance emulsion stability and facilitate the formation of micro- or nano-sized droplets, which significantly improve drug release and skin permeation. The hydrophilic–lipophilic balance (HLB) value of surfactants plays a crucial role in determining the type and stability of the emulsion. Moreover, surfactants can influence drug permeation by interacting with skin lipids and altering the barrier properties of the stratum corneum .

4.3 Gelling Agents and Polymers

Gelling agents are responsible for converting the emulsion into a gel-like structure, thereby improving the viscosity, stability, and application properties of the formulation. Commonly used gelling agents include Carbopol, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and xanthan gum.

These polymers form a three-dimensional network that entraps the emulsion droplets, enhancing formulation stability and preventing phase separation. Gelling agents also influence drug release by controlling diffusion through the gel matrix and improving bioadhesion, which prolongs the residence time of the drug on the skin .Furthermore, the rheological properties imparted by gelling agents contribute to better spreadability and patient compliance. Natural polymers offer additional advantages such as biocompatibility and biodegradability, although they may be susceptible to microbial degradation .

4.4 Penetration Enhancers

Penetration enhancers are incorporated into emulgel formulations to overcome the barrier properties of the stratum corneum and improve drug permeation. These agents function by disrupting the lipid structure of the skin, increasing drug solubility, or enhancing partitioning into the skin layers.

Common penetration enhancers include ethanol, propylene glycol, oleic acid, and terpenes. Their presence significantly improves drug flux and bioavailability by facilitating drug transport across the skin barrier. Additionally, the combined effect of penetration enhancers and the emulsion system leads to improved therapeutic outcomes .

4.5 Excipients and Stabilizers

Excipients play a supportive yet essential role in ensuring the stability, safety, and acceptability of emulgel formulations. These include preservatives, antioxidants, pH modifiers, and humectants.

- **Preservatives** (e.g., parabens) prevent microbial growth
- **Antioxidants** (e.g., tocopherol) prevent oxidative degradation
- **Humectants** (e.g., glycerin) improve skin hydration
- **pH adjusters** maintain formulation compatibility with skin

The proper selection of excipients ensures product stability, enhances shelf-life, and improves patient acceptability. Additionally, formulation factors such as excipient compatibility and concentration significantly influence drug release and permeation behavior

5. Formulation Strategies and Preparation Techniques

The development of emulgel formulations requires a systematic approach that integrates formulation design, process optimization, and scalability considerations. The selection of appropriate formulation strategies and preparation techniques plays a critical role in determining drug stability, release behavior, and transdermal permeation efficiency.

5.1 Conventional Preparation Methods

The conventional method of emulgel preparation involves a **three-step process**, including preparation of the gel base, formulation of the emulsion, and incorporation of the emulsion into the gel matrix.

Initially, the gel base is prepared by dispersing a suitable gelling agent (e.g., Carbopol or HPMC) in purified water with continuous stirring, followed by pH adjustment using neutralizing agents such as triethanolamine. Subsequently, an oil-in-water (O/W) or water-in-oil (W/O) emulsion is formulated by mixing the oil phase and aqueous phase separately, each containing appropriate surfactants and co-surfactants. The emulsion is then incorporated into the gel base with continuous stirring or homogenization to obtain a uniform emulgel system .

This method is widely used due to its simplicity, cost-effectiveness, and ease of formulation. The resulting emulgel exhibits improved stability, controlled drug release, and enhanced skin permeation due to the combined effect of emulsion droplets and gel matrix .

5.2 Optimization Approaches (DoE and QbD)

Modern formulation development emphasizes the use of **Design of Experiments (DoE)** and **Quality by Design (QbD)** approaches to systematically optimize formulation variables. These strategies allow the identification of critical formulation and process parameters such as oil concentration, surfactant ratio, polymer concentration, and mixing conditions.

DoE enables the evaluation of multiple variables simultaneously and helps establish relationships between independent variables and formulation responses such as viscosity, drug release, and permeation. QbD further ensures consistent product quality by defining a design space and controlling variability during formulation development.

Recent studies highlight that optimization techniques significantly improve formulation robustness, reproducibility, and scalability, making them essential tools in modern pharmaceutical development .

5.3 Advanced Preparation Techniques

Recent advancements in emulgel technology have led to the development of **novel preparation techniques**, particularly for nanoemulgels and advanced delivery systems.

High-Pressure Homogenization

This technique reduces droplet size to the nanoscale, improving drug solubility, stability, and permeation. Smaller droplet size increases surface area, enhancing drug release and absorption.

Ultrasonication

Ultrasonication uses ultrasonic waves to produce fine emulsions with uniform droplet size distribution. It is widely used for preparing nanoemulgels with improved physicochemical properties.

Microfluidization

This technique involves forcing fluids through microchannels under high pressure to produce stable nanoemulsions with narrow size distribution, leading to improved formulation stability and bioavailability.
These advanced techniques improve formulation performance by enhancing thermodynamic stability, reducing particle size, and facilitating targeted drug delivery .

5.4 Scale-Up Considerations

Scaling up emulgel formulations from laboratory to industrial level presents several challenges. Factors such as mixing efficiency, shear rate, temperature control, and equipment selection significantly influence the final product quality.
Maintaining uniform droplet size distribution and consistency during large-scale production is critical. Additionally, stability issues such as phase separation and viscosity changes must be carefully addressed. Regulatory requirements also necessitate strict quality control and validation procedures.
The adoption of QbD principles and process analytical technologies (PAT) can facilitate successful scale-up by ensuring reproducibility and compliance with regulatory standards

6. Characterization and Evaluation Parameters

The evaluation of emulgel formulations is essential to ensure their quality, stability, safety, and therapeutic efficacy. A comprehensive characterization involves physicochemical, rheological, and biological assessments to determine the performance of the formulation. These parameters collectively influence drug release, skin permeation, and patient acceptability.

6.1 Physicochemical Properties

Physicochemical evaluation includes parameters such as **appearance, color, homogeneity, consistency, and pH**. Visual inspection is carried out to detect any phase separation, grittiness, or instability. The pH of the formulation is typically maintained within the physiological skin range (5.5–6.5) to avoid irritation and ensure compatibility with the skin .
Drug content uniformity is another critical parameter, ensuring consistent drug distribution throughout the formulation. Additionally, globule size and polydispersity index (PDI) are evaluated, especially in nanoemulgels, as they directly influence drug release and permeation behavior .

6.2 Rheological Behavior

Rheological studies are performed to determine the **viscosity, flow behavior, and spreadability** of emulgels. These properties influence the ease of application and retention at the site of administration. Viscosity is typically measured using a Brookfield viscometer under controlled conditions.
Emulgels generally exhibit **non-Newtonian, pseudoplastic flow behavior**, which facilitates easy spreading under shear stress while maintaining stability at rest. Spreadability tests are conducted using slide-based methods to evaluate the formulation’s ability to distribute uniformly on the skin surface .

6.3 Drug Release and Kinetics

In vitro drug release studies are conducted using diffusion cells (e.g., Franz diffusion cell) to evaluate the release profile of the drug from the emulgel matrix. These studies help in understanding the mechanism of drug release, which often follows **diffusion-controlled kinetics** such as Higuchi or Korsmeyer–Peppas models.

The release profile is influenced by factors such as droplet size, polymer concentration, and viscosity of the gel matrix. Controlled and sustained release behavior is a key advantage of emulgel systems, enhancing therapeutic efficacy .

6.4 Skin Permeation and Retention Studies

Ex vivo and in vivo permeation studies are performed to evaluate the ability of the drug to penetrate through the skin layers. Franz diffusion cells using animal or human skin models are commonly employed to measure drug flux, permeability coefficient, and cumulative drug release.

Skin retention studies assess the amount of drug retained within different skin layers, which is crucial for localized therapy. Advanced emulgel systems, particularly nanoemulgels, have demonstrated improved permeation and retention due to enhanced interaction with the stratum corneum .

6.5 Stability and Shelf-Life Assessment

Stability studies are conducted to evaluate the physical and chemical stability of emulgel formulations under different environmental conditions such as temperature, humidity, and light. Parameters such as **phase separation, viscosity changes, pH variation, and drug degradation** are monitored over time.

Accelerated stability studies are performed as per regulatory guidelines to predict shelf life and ensure product reliability. Centrifugation and freeze–thaw cycles are also used to assess thermodynamic stability of the formulation

7. Recent Advances in Emulgel Technology

Recent years have witnessed significant progress in emulgel technology, driven by advancements in nanotechnology, polymer science, and targeted drug delivery approaches. These innovations have enhanced drug solubility, permeability, stability, and therapeutic efficacy, making emulgels a promising platform for transdermal drug delivery.

7.1 Nanoemulgels and Nanostructured Systems

Nanoemulgels represent one of the most important advancements in emulgel technology. These systems consist of nano-sized emulsion droplets incorporated into a gel matrix, offering a large surface area that enhances drug solubility and permeation across the skin. Nanoemulgels are particularly effective for poorly water-soluble drugs, as they improve bioavailability and ensure controlled drug release.

The nanoscale droplet size facilitates deeper penetration into the stratum corneum and improves drug distribution within skin layers. Additionally, surfactants and co-surfactants in nanoemulgels act as penetration enhancers, further improving drug flux . Studies have demonstrated their effectiveness in delivering anti-inflammatory and analgesic drugs with improved therapeutic outcomes .

7.2 Stimuli-Responsive and Smart Emulgels

Stimuli-responsive or “smart” emulgels are designed to release drugs in response to specific physiological triggers such as pH, temperature, or enzymes. These systems provide controlled and site-specific drug delivery, minimizing side effects and enhancing therapeutic efficiency.

For example, thermoresponsive polymers can undergo phase transitions at body temperature, enabling controlled drug release at the target site. Such systems are gaining attention for personalized medicine and targeted therapy applications. The integration of smart polymers with emulgel systems has significantly expanded their functional capabilities .

7.3 Use of Natural and Biodegradable Polymers

Recent advances emphasize the use of natural and biodegradable polymers such as chitosan, alginate, xanthan gum, and cellulose derivatives. These materials offer advantages including biocompatibility, reduced toxicity, and environmental sustainability.

Natural polymers also enhance bioadhesion and prolong the residence time of the formulation on the skin, thereby improving drug absorption. Moreover, their ability to form stable gel networks contributes to improved formulation stability and controlled drug release. The shift toward green and sustainable excipients is a key trend in modern emulgel development .

7.4 Herbal and Phytopharmaceutical-Based Emulgels

Herbal emulgels have gained popularity due to the increasing demand for natural and safer therapeutic options. These formulations incorporate plant-derived active compounds such as flavonoids, essential oils, and alkaloids.

Herbal emulgels offer advantages such as reduced side effects, enhanced patient acceptability, and synergistic therapeutic effects. They have been widely investigated for applications in wound healing, anti-inflammatory therapy, and antimicrobial treatments. Recent studies highlight their effectiveness in improving skin conditions and promoting faster healing .

7.5 Targeted and Controlled Drug Delivery Approaches

Advanced emulgel systems are being developed to achieve targeted and controlled drug delivery. These systems utilize nanoscale carriers, ligands, and stimuli-responsive components to deliver drugs to specific sites within the skin or systemic circulation.

Targeted emulgels improve therapeutic efficacy by concentrating the drug at the desired site while minimizing systemic exposure. Controlled release mechanisms ensure sustained drug delivery over extended periods, reducing dosing frequency and improving patient compliance.

Recent research demonstrates that optimized nanoemulgel formulations can significantly enhance drug bioavailability and therapeutic outcomes, particularly in chronic conditions such as arthritis and dermatological disorders

8. Therapeutic Applications and Case Studies

Emulgel technology has demonstrated extensive applicability in both topical and transdermal drug delivery due to its ability to enhance drug solubility, permeability, and retention at the site of action. Recent advancements, particularly in nanoemulgel systems, have further expanded their therapeutic potential across various clinical conditions, including inflammatory disorders, infections, wound healing, and systemic drug delivery .

8.1 Anti-inflammatory and Analgesic Applications

Emulgels are widely used for the topical delivery of anti-inflammatory and analgesic drugs such as diclofenac, ibuprofen, and ketoprofen. These formulations provide localized drug action, reducing systemic side effects commonly associated with oral administration.

A notable case study demonstrated that diflunisal-loaded nanoemulgel exhibited enhanced anti-inflammatory activity in animal models compared to conventional formulations, due to improved drug retention and sustained release . Similarly, nanoemulgels have been shown to enhance the bioavailability of hydrophobic anti-inflammatory drugs by improving their solubility and permeation across the skin barrier .

8.2 Antifungal and Antimicrobial Delivery

Emulgels have shown significant potential in the treatment of microbial infections, including fungal and bacterial skin diseases. Their ability to deliver drugs locally with prolonged retention enhances therapeutic efficacy while minimizing systemic exposure.

Nanoemulgel-based formulations have been investigated for delivering antimicrobial agents such as clotrimazole and ketoconazole, showing improved penetration into infected tissues and enhanced antifungal activity. These systems are particularly beneficial for treating chronic skin infections where sustained drug release is required .

8.3 Hormonal and Systemic Drug Delivery

Emulgels are also explored for transdermal delivery of hormones and other systemic drugs. This route avoids first-pass metabolism and ensures steady plasma drug levels.

Studies have shown that nanoemulgel formulations improve the transdermal delivery of lipophilic drugs, enabling controlled systemic absorption. The enhanced permeation properties of nanoemulgels make them suitable for drugs with poor oral bioavailability .

8.4 Dermatological and Cosmetic Applications

Emulgels are extensively used in dermatology and cosmetology due to their non-greasy nature, ease of application, and improved patient compliance. They are used in the treatment of acne, psoriasis, eczema, and other skin disorders.

For instance, nanoemulgel formulations have been developed for acne treatment, providing improved drug penetration and reduced irritation compared to conventional topical systems . Additionally, emulgels are used in cosmetic formulations for delivering active ingredients such as antioxidants, vitamins, and essential oils.

8.5 Wound Healing and Cancer Therapy (Emerging Applications)

Recent studies highlight the use of nanoemulgels in **wound healing and cancer therapy**. These systems provide a moist environment, controlled drug release, and enhanced penetration, which are critical for effective wound management.

Nanoemulgels have also been investigated for delivering anticancer agents to skin tumors, offering targeted therapy with reduced systemic toxicity. Their ability to improve drug accumulation at the site of action makes them promising candidates for advanced therapeutic applications

9. Critical Analysis: Advantages and Limitations

Emulgel technology has emerged as a promising platform for transdermal drug delivery by combining the advantages of emulsions and gels. However, despite its significant benefits, cert ain limitations and challenges still restrict its widespread clinical and industrial application. A critical evaluation of these aspects is essential for understanding its current status and future potential.

9.1 Comparative Advantages

Emulgels offer several advantages over conventional topical and transdermal drug delivery systems. One of the primary benefits is their ability to incorporate both **hydrophilic and lipophilic drugs**, overcoming the solubility limitations associated with traditional gels . The presence of an oil phase enables efficient delivery of hydrophobic drugs, which are otherwise difficult to formulate.

Another key advantage is **enhanced drug release and permeation**. Compared to ointments and creams, emulgels provide a dual-controlled release mechanism due to the combined effect of the emulsion and gel matrix, leading to improved therapeutic efficacy . Furthermore, the aqueous gel base reduces greasiness, improves spreadability, and enhances patient compliance.

Emulgels also exhibit **better stability and drug loading capacity** compared to other novel delivery systems such as liposomes and niosomes, which often suffer from leakage and low entrapment efficiency . Additionally, their **ease of preparation, low cost, and scalability** make them attractive for industrial applications.

From a clinical perspective, emulgels enable **localized drug delivery with reduced systemic side effects**, particularly in conditions such as inflammation and arthritis. Their ability to provide sustained drug release further contributes to improved therapeutic outcomes and patient adherence .

9.2 Current Limitations and Challenges

Despite these advantages, emulgels also present several limitations. One of the major challenges is **limited skin permeability**, as the stratum corneum remains a significant barrier, particularly for drugs with high molecular weight or poor lipophilicity . This restricts their applicability for certain therapeutic agents.

Another concern is the potential for **skin irritation and allergic reactions**, especially due to the presence of surfactants, preservatives, or penetration enhancers in the formulation . These issues may affect patient compliance and limit long-term use.

Formulation-related challenges such as **physical instability**, including phase separation, creaming, and bubble entrapment during preparation, can affect product quality and shelf life . Maintaining uniformity and consistency during large-scale manufacturing is also a significant hurdle.

Additionally, emulgels may exhibit **limited suitability for macromolecules or large drug particles**, as their penetration through the skin is inherently restricted . This limits their use in delivering biologics and peptide-based drugs.

9.3 Gaps in Existing Research

Although substantial progress has been made in emulgel technology, several research gaps remain. One of the most critical issues is the **lack of extensive clinical studies** validating their long-term safety and efficacy in humans. Most studies are still limited to in vitro or ex vivo evaluations.

Another gap is related to **standardization of formulation and evaluation methods**, which varies significantly across studies, making comparison and reproducibility difficult. Furthermore, **limited regulatory guidelines** specific to emulgel systems pose challenges for commercialization and approval.

There is also a need for further research into **advanced drug delivery strategies**, such as targeted and stimuli-responsive emulgels, to overcome existing limitations. Integration with nanotechnology and smart delivery systems holds promise but requires more in-depth investigation.

10. Regulatory and Industrial Perspectives

10.1 Regulatory Considerations (FDA/EMA Guidelines)

The regulatory approval of emulgel formulations falls under the broader category of topical semisolid dosage forms, which are governed by stringent guidelines from regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These formulations present unique regulatory challenges due to their complex microstructure, multiphase composition, and variable drug release behavior [1].

One of the key regulatory requirements is the demonstration of quality, safety, and efficacy through well-defined Chemistry, Manufacturing, and Controls (CMC) parameters. Regulatory agencies emphasize the importance of qualitative (Q1) and quantitative (Q2) sameness, as well as microstructural similarity (Q3), especially for generic products. Even minor variations in excipient composition or processing conditions can significantly affect drug release and skin permeation [1].

In the United States, the FDA provides guidance through documents such as the SUPAC-SS (Scale-Up and Post Approval Changes for Semisolid Dosage Forms), which outlines requirements for formulation changes, manufacturing processes, and site transfers. It also recommends in vitro release testing (IVRT) and in vitro permeation testing (IVPT) as critical tools for ensuring product equivalence and performance consistency .Similarly, the EMA has proposed guidelines focusing on bioequivalence for topical products, where traditional pharmacokinetic studies may not be feasible. Alternative approaches such as dermatopharmacokinetic studies, tape stripping, and pharmacodynamic endpoints are often required to demonstrate therapeutic equivalence [1].Another important consideration is the classification of emulgel products, which may vary depending on their intended use (cosmetic vs. pharmaceutical). Misclassification can lead to regulatory delays and affect market approval, highlighting the need for clear regulatory strategies during product development [2].

1002 Industrial Feasibility and Scalability

From an industrial perspective, emulgel technology offers promising opportunities due to its ease of formulation, cost-effectiveness, and patient-friendly characteristics. However, large-scale manufacturing introduces several challenges related to process reproducibility, stability, and quality control.

One of the primary concerns in industrial production is maintaining batch-to-batch consistency, particularly in terms of droplet size distribution, viscosity, and microstructure. These parameters directly influence drug release and therapeutic performance. Scaling up from laboratory to industrial production requires careful optimization of mixing speed, temperature control, homogenization techniques, and equipment selection [2].

Additionally, the stability of emulgel formulations during storage and transportation is critical. Issues such as phase separation, creaming, and viscosity changes must be addressed through appropriate formulation design and packaging strategies. The selection of suitable emulsifiers, gelling agents, and preservatives plays a crucial role in ensuring long-term stability [3].

Industrial adoption is also influenced by market demand and commercial viability. Compared to other dosage forms, topical semisolid products often generate lower revenue margins, which can limit investment in research and development. Despite this, emulgels have gained increasing attention due to their enhanced therapeutic performance, versatility, and applicability in both pharmaceutical and cosmetic industries [1].

Recent advancements have demonstrated the successful translation of emulgel systems from bench to bedside, supported by clinical studies, patents, and commercial formulations. However, achieving widespread commercialization requires overcoming regulatory complexities, optimizing manufacturing processes, and ensuring compliance with global quality standards [2].

10.3 Industrial Challenges and Opportunities

While emulgel technology holds significant promise, several challenges must be addressed to facilitate its industrial adoption:

- **Regulatory complexity:** Lack of standardized guidelines specific to emulgels

- **Scale-up difficulties:** Maintaining microstructural integrity during large-scale production
- **Quality control issues:** Ensuring consistency in rheological and release properties
- **Limited clinical data:** Need for more in vivo and clinical validation studies

Despite these challenges, opportunities for growth are substantial. The increasing demand for non-invasive drug delivery systems, coupled with advancements in nanotechnology and smart delivery systems, is expected to drive the future development and commercialization of emulgel-based products [

11. Future Perspectives and Research Directions

The rapid evolution of emulgel technology has opened new avenues for enhancing transdermal drug delivery. Despite significant progress, ongoing research continues to focus on overcoming current limitations and expanding the applicability of emulgels through innovative approaches and advanced technologies.

11.1 Integration of Nanotechnology

One of the most promising directions in emulgel research is the incorporation of **nanotechnology-based systems**, such as nanoemulgels, nanostructured lipid carriers, and polymeric nanoparticles. These systems improve drug solubility, enhance permeation across the skin, and enable targeted delivery. The reduced droplet size in nanoemulgels increases surface area, facilitating deeper penetration and improved therapeutic outcomes [1].

Future research is expected to focus on **multifunctional nanocarriers**, capable of combining diagnostic and therapeutic functions (theranostics), as well as improving stability and scalability for clinical applications.

11.2 Development of Stimuli-Responsive and Smart Emulgels

The design of **stimuli-responsive (smart) emulgels** represents a significant advancement in controlled drug delivery. These systems respond to external or internal stimuli such as pH, temperature, light, or enzymatic activity to release drugs in a controlled and site-specific manner.

For example, temperature-sensitive or pH-responsive polymers can be used to trigger drug release only at diseased sites, minimizing systemic side effects and enhancing therapeutic efficiency. Future research will likely explore **multi-stimuli responsive systems** for precise and personalized drug delivery [2].

11.3 Use of Novel Polymers and Biodegradable Materials

The exploration of **biodegradable, biocompatible, and natural polymers** is gaining increasing attention in emulgel development. Polymers such as chitosan, alginate, and cellulose derivatives offer advantages including improved safety, reduced toxicity, and enhanced bioadhesion.

Future studies are expected to focus on **green formulation approaches**, utilizing sustainable materials and eco-friendly processes. Additionally, the development of **functional polymers** with inherent therapeutic or permeation-enhancing properties represents a promising area of innovation [3].

11.4 Personalized and Targeted Drug Delivery

Advances in pharmaceutical sciences are moving toward **personalized medicine**, where drug delivery systems are tailored to individual patient needs. Emulgels can be customized based on factors such as skin type, disease condition, and pharmacokinetic requirements.

Targeted delivery strategies, including ligand-mediated systems and site-specific formulations, are expected to enhance therapeutic efficacy while minimizing adverse effects. This approach is particularly relevant for chronic dermatological conditions and localized therapies [4].

11.5 Expansion into New Therapeutic Areas

While emulgels are widely used in dermatology, their application is expanding into other therapeutic domains, including:

- **Pain management and arthritis**
- **Hormonal and systemic delivery**
- **Cosmeceuticals and aesthetic medicine**
- **Antimicrobial and antiviral therapies**

Emerging research also suggests potential applications in **ocular, nasal, and mucosal drug delivery systems**, further broadening the scope of emulgel technology [3].

11.6 Advanced Manufacturing and Scale-Up Technologies

Future research will emphasize the development of **robust and scalable manufacturing techniques**, such as high-pressure homogenization, ultrasonication, and continuous processing. The integration of **Quality by Design (QbD)** principles and Process Analytical Technology (PAT) will ensure consistent product quality and regulatory compliance.

Additionally, the use of **3D printing and digital manufacturing technologies** may enable the production of customized emulgel formulations with precise control over composition and drug release characteristics [2].

11.7 Clinical Translation and Regulatory Harmonization

Despite promising preclinical results, the clinical translation of emulgel formulations remains limited. Future research should focus on:

- Conducting **large-scale clinical trials**
- Establishing **standardized evaluation protocols**
- Developing **regulatory guidelines specific to emulgels**

Harmonization of global regulatory frameworks will be essential to facilitate commercialization and ensure the widespread adoption of emulgel-based drug delivery systems [4].

11.8 Artificial Intelligence and Digital Formulation Design

The integration of **artificial intelligence (AI) and machine learning (ML)** in pharmaceutical development is expected to revolutionize emulgel formulation. AI-driven models can predict optimal formulation parameters, stability profiles, and drug release behavior, significantly reducing development time and cost.

Future research may focus on **data-driven formulation design**, enabling rapid screening and optimization of emulgel systems for specific therapeutic applications.

11.9 Challenges and Opportunities

Although emulgel technology offers numerous advantages, challenges such as **long-term stability, large-scale production, and regulatory approval** remain. However, continued innovation in materials science, nanotechnology, and pharmaceutical engineering is expected to overcome these limitations and unlock the full potential of emulgels [2], [3].

CONCLUSION

Emulgel technology has emerged as a highly promising and versatile platform for enhancing transdermal drug delivery, effectively addressing the limitations associated with conventional topical and transdermal systems. By integrating the advantages of both emulsions and gels, emulgels provide a dual-controlled drug release mechanism, improved drug solubilization, and enhanced skin permeation, particularly for poorly water-soluble drugs .Recent advancements in emulgel technology, including the development of nanoemulgels, incorporation of novel polymers, and use of penetration enhancers, have significantly improved drug bioavailability, stability, and therapeutic efficacy. These innovations have expanded the applicability of emulgels across a wide range of therapeutic areas, such as anti-inflammatory, antifungal, analgesic, and dermatological treatments . Furthermore, the favorable physicochemical properties of emulgels—such as non-greasy texture, good spreadability, thixotropic behavior, and patient acceptability—make them superior to many conventional semisolid formulations .Despite these advantages, certain challenges remain, including issues related to long-term stability, large-scale manufacturing, and variability in skin permeability. Additionally, limited clinical data and regulatory complexities continue to hinder the widespread commercialization of advanced emulgel systems. Addressing these challenges through standardized evaluation methods, robust formulation strategies, and regulatory harmonization will be essential for successful translation from research to clinical application.Overall, emulgel-based systems represent a significant advancement in transdermal drug delivery, offering a unique combination of efficacy, safety, and patient compliance. With continued research and technological innovations, emulgels hold strong potential to become a cornerstone in modern drug delivery, particularly in the era of personalized and targeted therapeutics

REFERENCES

1. B. W. Barry, "Novel mechanisms and devices to enable successful transdermal drug delivery," *European Journal of Pharmaceutical Sciences*, vol. 14, no. 2, pp. 101–114, 2001. doi: 10.1016/S0928-0987(01)00167-1.
2. A. Alexander, A. Khichariya, S. Gupta, D. Patel, S. Giri, and D. K. Tripathi, "Recent expansions in an emergent novel drug delivery technology: Emulgel," *Journal of Controlled Release*, vol. 171, no. 2, pp. 122–132, 2013. doi: 10.1016/j.jconrel.2013.06.030.
3. S. Shakeel, M. Ramadan, and F. Ahmed, "Investigation of nanoemulsion as a carrier for transdermal delivery," *Drug Development and Industrial Pharmacy*, vol. 35, no. 8, pp. 1090–1102, 2009. doi: 10.1080/03639040902774296.
4. R. L. Bronaugh and H. I. Maibach, *Percutaneous Absorption: Drugs—Cosmetics—Mechanisms—Methodology*, 3rd ed. New York, USA: Marcel Dekker, 2005. doi: 10.1201/9780849340516.
5. M. L. Stojanovic *et al.*, "Emulgels: Promising carrier systems for drugs and bioactive compounds," *Polymers*, vol. 15, no. 10, 2023. doi: 10.3390/polym15102302.
6. B. M. Patel *et al.*, "Emulgel approach to formulation development: A review," *Bioscience Biotechnology Research Asia*, vol. 18, no. 3, 2021. doi: 10.13005/bbra/2931.
7. D. S. Denei *et al.*, "A review on formulation and evaluation of emulgel," 2022.
8. J. J. Romero *et al.*, "Emulsion-filled gels and their applications," *Trends in Food Science & Technology*, 2019. doi: 10.1016/j.tifs.2019.02.043.
9. M. Talat *et al.*, "Emulgel: An effective drug delivery system," *Drug Development and Industrial Pharmacy*, 2021. doi: 10.1080/03639045.2021.1993889.
10. E. Ganju *et al.*, "Emulgel towards novel formulation development: A comprehensive review," *International Journal of Medical and*

Pharmaceutical Sciences, 2024. doi: 10.31782/IJMPS.2024.14101.
11. "Nanoemulgel: A comprehensive review of formulation strategies," *Micro and Nano Systems*, 2025. doi: 10.2174/0118764029316500240904074317.
12. B. A. Khan *et al.*, "Fabrication and characterization of pharmaceutical emulgel co-loaded with naproxen-eugenol," *Gels*, vol. 8, no. 10, 2022. doi: 10.3390/gels8100608.
13. S. Sulthana *et al.*, "Development and evaluation of emulgel for psoriasis," *Inflammopharmacology*, vol. 31, 2023. doi: 10.1007/s10787-022-01131-7.
14. V. Kumari and M. Bajpai, "Formulation and characterization of lornoxicam emulgel," *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 2024. doi: 10.2174/0118715230289163240703075629.
15. M. Karthick *et al.*, "An overview on empirical characterization of emulgel," *International Journal of Scientific Research*, 2023. doi: 10.21275/SR23921115212.
16. D. K. Lal *et al.*, "An overview of nanoemulgels for bioavailability enhancement," *Pharmaceutics*, vol. 15, no. 4, 2023. doi: 10.3390/pharmaceutics15041187.
17. M. R. Donthi *et al.*, "Nanoemulgel: A novel nano carrier for topical drug delivery," *Pharmaceutics*, vol. 15, no. 1, 2023. doi: 10.3390/pharmaceutics15010164.
18. K. Sghier *et al.*, "Nanoemulgels for the treatment of skin diseases," *Gels*, vol. 10, no. 1, 2024. doi: 10.3390/gels10010045.
19. P. R. Kumbhar *et al.*, "Versatility of emulgel in topical drug delivery transforming its expedition from bench to bedside," *Expert Opinion on Drug Delivery*, vol. 22, no. 1, pp. 55–68, 2025. doi: 10.1080/17425247.2024.2439457.
20. R. Rajni *et al.*, "Nanoemulgel for osteoarthritis treatment," *Therapeutic Delivery*, 2024. doi: 10.4155/tde-2023-0109.
21. S. V. Rao *et al.*, "Effectiveness of topical nanoemulgel in wound healing," *Journal of Population Therapeutics and Clinical Pharmacology*, 2023. doi: 10.53555/jptcp.v30i3.3170.
22. S. Jacob and A. B. Nair, "Nanoemulgels as advanced topical drug delivery systems: Therapeutic applications," *Pharmaceutics*, vol. 19, no. 2, 2026. doi: 10.3390/ph19020247.
23. M. A. Khan *et al.*, "Nanoemulgel for enhanced anti-inflammatory activity," 2020. doi: 10.2174/1574891X14666190717111531.
24. J. Ahmad *et al.*, "Topical nanoemulgel for skin disorders," *Recent Patents on Anti-Infective Drug Discovery*, 2019. doi: 10.2174/1574891X14666181129115213.
25. V. Verma, "Nanoemulgel: A revolutionary approach," *International Journal of Comprehensive and Advanced Pharmacology*, 2021. doi: 10.18231/j.ijcaap.2021.005.
26. D. Nandgude, "Emulgel: A comprehensive review for topical delivery," *Asian Journal of Pharmaceutics*, 2018. doi: 10.22377/ajp.v12i02.2366.
27. A. Sinha *et al.*, "Emulgels: A promising topical drug delivery system for arthritis management and care," *Pharmaceutical Development and Technology*, vol. 29, no. 1, pp. 25–39, 2024. doi: 10.1080/10837450.2023.2289170.
28. F. Vanpariya *et al.*, "Emulgel: A review," *International Journal of Scientific Research*, 2021. doi: 10.21275/SR21311095015.
29. T. Ilić, I. Pantelić, and S. Savić, "The implications of regulatory framework for topical semisolid drug products: From critical quality and performance attributes towards

establishing bioequivalence," *Pharmaceutics*, vol. 13, no. 5, p. 710, 2021. doi: 10.3390/pharmaceutics13050710.

30. A. Jain *et al.*, "Emulgel: A cutting edge approach for topical drug delivery system," *Current Drug Research Reviews*, vol. 17, no. 2, pp. 217–236, 2025. doi: 10.2174/0125899775278612240129055753.
31. Ritu *et al.*, "Emulgel: An effective drug delivery system," *Research Journal of Pharmacy and Technology*, vol. 16, no. 6, pp. 2754–2758, 2023. doi: 10.52711/0974-360X.2023.00452.

HOW TO CITE: Swati Ojha, Jyoti Yadav, Recent Advances in Emulgel Technology for Enhanced Transdermal Drug Delivery, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 59-75, https://doi.org/10.5281/zenodo.19369102